Ascentage raises $126m in first biotech IPO of 2025
1 day ago · Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, raising $126 million for its pipeline of small-molecule cancer drugs.
Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to …
5 days ago · Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly support late-stage clinical development of two medicines that could ...
Ascentage Pharma Announces Closing of U.S. Initial Public Offering
7 hours ago · About Ascentage Pharma. Ascentage Pharma is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. ... Chinese Biotech Ascentage Aims For $134M IPO. January 22, 2025 · 2 min read · Tristan Manalac. BioSpace ...
Ascentage Pharma raises $126m in first biotech IPO of 2025
5 days ago · Ascentage sold 7,325,000 American Depositary shares at $17.25 each. Credit: Andrey Zhuravlev via Getty Images. China-based biotech Ascentage Pharma has raised $126m in a US initial public offering (IPO), marking the first biotech IPO of 2025. The company sold 7,325,000 American Depositary shares at ...
Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to
Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly support late-stage clinical development of two medicines that could ...
Ascentage Pharma Closes IPO of 7.33 Million American …
7 hours ago · -- Ascentage Pharma said late Tuesday that it closed its initial public offering of almost 7.33 million American depositary shares at $17.25 per ADS, raising about $126.4 million in gross... -January 28, 2025 at 05:21 pm EST - MarketScreener
Ascentage Pharma Announces Pricing of U.S. Initial Public Offering
ROCKVILLE, Md. and SUZHOU, China, Jan. 23, 2025 — Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the pricing of its U.S. initial public offering of 7,325,000 American depositary shares (“ADSs”), at a public offering price of $17.25 per ADS, before underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. The Read More ›
Ascentage Pharma raises $126M via U.S. IPO (update)
4 days ago · Ascentage Pharma raises $126M via U.S. IPO (update) Jan. 24, 2025 10:27 AM ET Ascentage Pharma Group International (AAPGV) Stock , TAK Stock , IPO PFE , MRK , AZN , IVBIY , IVBXF By: Val Brickates ...
Ascentage Pharma’s US Shares Climb After $126 Million IPO
4 days ago · Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s US trading debut, after pricing its $126.4 million initial public ...
Ascentage prices first biotech IPO of 2025, raising $126M
6 days ago · Ascentage was formed in Hong Kong in 2009, and has headquarters in Suzhou as well as in Rockville, Maryland. The company generated 877 million yuan in revenue, or about $125 million, over the first nine months of 2024, according to its IPO filing. Most came from the $100 million Takeda paid to license olverembatinib.
- Some results have been removed